CTAG3: A Potential Drug Target and Biomarker for Diseases Characterized By TCF7L1 Over-Expression

Target Name: CTAGE3P

NCBI ID: G220112

CTAGE3P

Other Name(s): CTAGE family member 3, pseudogene | CTAGE family, member 3, pseudogene | CTAGE3 | CTAGE-3

CTAG3: A Potential Drug Target and Biomarker for Diseases Characterized By TCF7L1 Over-Expression

CTAGE3P, also known as CTAGE family member 3, is a gene that encodes a protein known as CTAG3. The CTAG3 protein is a member of the CTAG family, which is characterized by the presence of a specific conserved domain called the carboxy-terminal alpha-helix (CTAHL). This protein is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract.

One of the unique features of CTAG3 is its ability to interact with other proteins, particularly with the protein known as TCF7L1. This interaction between CTAG3 and TCF7L1 has important implications for the function of both proteins and may be a potential drug target.

In addition to its interaction with TCF7L1, CTAG3 has also been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and the cytoskeleton. This suggests that CTAG3 may be a useful biomarker for the diagnosis and treatment of various diseases.

The potential drug target for CTAG3 is its interaction with TCF7L1, which is a protein that is expressed in many tissues throughout the body and is involved in the regulation of cell growth, differentiation, and survival. CTAG3 has been shown to interact with TCF7L1 and to play a role in the regulation of TCF7L1-mediated signaling pathways.

This interaction between CTAG3 and TCF7L1 raises the possibility that CTAG3 may be a useful target for the treatment of diseases that are characterized by the over-expression or dysfunction of TCF7L1. For example, some studies have suggested that the over-expression of TCF7L1 may contribute to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, CTAG3 may also be a useful biomarker for the diagnosis and treatment of various diseases. For example, the over-expression of CTAG3 has been shown to contribute to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that tracking the expression and function of CTAG3 may be a valuable tool for the diagnosis and treatment of these diseases.

In conclusion, CTAG3 is a gene that encodes a protein that is expressed in a variety of tissues throughout the body and is characterized by the presence of a specific conserved domain called the carboxy-terminal alpha-helix. The interaction between CTAG3 and the protein known as TCF7L1 has important implications for the function of both proteins and may be a potential drug target. Further research is needed to fully understand the role of CTAG3 in the regulation of cellular processes and to explore its potential as a biomarker for the diagnosis and treatment of various diseases.

Protein Name: CTAGE Family Member 3, Pseudogene

Functions: Tumor-associated antigen

The "CTAGE3P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTAGE3P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets